Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations

被引:25
作者
Barbosa, Fernando, Jr.
Gerlach, Raquel E.
Tanus-Santos, Jose E.
机构
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049900 Ribeirao Preto, Brazil
[2] Univ Sao Paulo, Dept Clin Toxicol & Food Sci Anal, Fac Pharmaceut Sci Ribeirao Preto, BR-14040903 Ribeirao Preto, Brazil
[3] Univ Sao Paulo, Dent Sch Ribeirao Preto, Dept Morphol Estomatol & Physiol, BR-14040904 Ribeirao Preto, Brazil
关键词
D O I
10.1111/j.1742-7843.2006.pto_392.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Matrix metalloprotemases (MMPs) are enzymes involved in the degradation of the extracellular matrix. MMP-2 and MMP-9 have been implicated in a variety of pathological conditions including cardiovascular and neoplastic diseases, and recent studies have shown that circulating concentrations of MMP-9 may be a marker helping in the diagnosis and prognosis of cardiovascular and neoplastic diseases. We investigated whether there is an association between plasma MMP-2 and MMP-9 activities and the concentrations of lead in whole blood (blood Pb) or plasma (plasma Pb) from 40 lead-exposed persons (22 men and 18 women). Plasma Ph was determined by inductively coupled plasma mass spectrometry (ICP-MS) and blood Pb by graphite furnace atomic absorption spectrometry (GF-AAS). Plasma MMP-2 and MMP-9 activities were measured by gelatin zymography. We found a significant correlation between pro-MMP-9 activity in plasma and blood Pb (r=0.454; P=0.003), and between pro-MMP-9 activity in plasma and plasma Ph (r=0.312; P= 0.049). No significant correlations were found between blood Pb or plasma Ph and plasma MMP-2. The association between pro-MMP-9 activity in plasma and both blood Ph and plasma Ph concentrations suggests a mechanism through which low lead exposure may increase the susceptibility to cardiovascular and neoplastic diseases. A causal relationship, however, remains to be proved.
引用
收藏
页码:559 / 564
页数:6
相关论文
共 33 条
[1]   Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure [J].
Altieri, P ;
Brunelli, C ;
Garibaldi, S ;
Nicolino, A ;
Ubaldi, S ;
Spallarossa, P ;
Olivotti, L ;
Rossettin, P ;
Barsotti, A ;
Ghigliotti, G .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (08) :648-656
[2]  
*ATSDR, 1999, TOX PROF LEAD
[3]   eNOS genotype-dependent correlation between whole blood lead and plasma nitric oxide products concentrations [J].
Barbosa, F ;
Sandrim, VC ;
Uzuelli, JA ;
Gerlach, RF ;
Tanus-Santos, JE .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2006, 14 (01) :58-64
[4]   A critical review of biomarkers used for monitoring human exposure to lead: Advantages, limitations, and future needs [J].
Barbosa, F ;
Tanus-Santos, JE ;
Gerlach, RF ;
Parsons, PJ .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2005, 113 (12) :1669-1674
[5]   Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J].
Blankenberg, S ;
Rupprecht, HJ ;
Poirier, O ;
Bickel, C ;
Smieja, M ;
Hafner, G ;
Meyer, J ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 107 (12) :1579-1585
[6]   Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects [J].
Demacq, C ;
de Souza, AP ;
Machado, AA ;
Gerlach, RF ;
Tanus-Santos, JE .
CLINICA CHIMICA ACTA, 2006, 365 (1-2) :183-187
[7]  
Farias E, 2000, INT J CANCER, V89, P389, DOI 10.1002/1097-0215(20000720)89:4<389::AID-IJC12>3.0.CO
[8]  
2-J
[9]   Matrix metalloproteinases in vascular remodeling and atherogenesis - The good, the bad, and the ugly [J].
Galis, ZS ;
Khatri, JJ .
CIRCULATION RESEARCH, 2002, 90 (03) :251-262
[10]   Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities [J].
Gerlach, RF ;
Uzuelli, JA ;
Souza-Tarla, CD ;
Tanus-Santos, JE .
ANALYTICAL BIOCHEMISTRY, 2005, 344 (01) :147-149